| Biomarker ID | 498 |
| PMID | 19894759 |
| Year | 2009 |
| Biomarker | e-FABP5, MCCC2, PPA2, Ezrin, and SLP2 |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in LNM PCa |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include(FABPP2):-PPAR signaling pathwayInterleukin-1 regulation of extracellular matrix |
| Experiment | Lymph Node Metastatic Prostate Cancer Vs Localised PCA |
| Type of Biomarker | Prognostic |
| Cohort | In total, 58 cases of PCa (localized PCa, N = 38); (LNM PCa, N= 20) and 30 cases of BPH were recollected. de anonymous according to the ethical and legal standards. Altogether, real time RT-PCR was performed on 16 localized PCa tissues, 16 LNM PCa tissues, and 16 BPH tissues. Western blotting was performed on 9 localized PCa tissues, 9 LNM PCa tissues and 9 BPH tissues. Paraffin-embedded specimens from 48 cases of localized PCa, 27 cases of LNM PCa and 30 cases of BPH were used to validate the expression of selected differently expressed proteins by IHC methods. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.01 |
| Method Used | real time PCR, Western blotting, and immunohistochemistry staining |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on Independent Patient Dataset |
| Technical Name | FABP5: MCCC2: PPA2: EZR: SYTL2 |